CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA.

Slides:

Advertisements

Similar presentations

Clinical Genomics Sub-team Sub-team is one of three that evolved out of the DIA Pharmacogenomics Standards Workshop. Workshop was product of collaborative.

Advertisements

Regulatory Framework Leigh Shaw, Director.

Effectiveness Evaluation for Production Drugs Crystal Groesbeck, Ph.D Division of Production Drugs.

Use of Foreign Data for Approval Ann Farrell, MD Division of Oncology Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Electronic Common Technical Document (eCTD) Update Jon Clark ICH M2 Deputy Topic Leader January 21, 2003.

Drug Development Lynnda Reid, Ph.D. Pharmacology/Toxicology Reviewer Center for Drug Evaluation and Research (CDER) Rafael Ponce, Ph.D., DABT Senior Scientist.

SEND Standard for the Exchange of Nonclinical Data

Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.

1 Pharmacology/Toxicology information to submit an IND for an anticancer drug.

1 Everything You Wanted to Know About GLPs…. but were afraid to ask Janet Rose Christensen, M.S.P.H. Vice President, Regulatory Affairs and Quality AVI.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Roger D.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.

Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.

What Do Toxicologists Do?

Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.

Stefan Franzén Introduction to clinical trials.

Toxicology in Drug Development

+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.

U of Arizona Innovation Conference 20 September 2011 Marlene E. Haffner, MD, MPH Haffner Associates, LLC.

Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.

Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals

Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.

Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.

Food and Drug Administration Center for Biologics Evaluation and Research The Office of Cellular, Tissue and Gene Therapies Web Seminar Series presents:

Structure of Dossier of Medicinal Product- Q part

Guidance for Industry M4S: The CTD-Safety

Justina A. Molzon, MS Pharm, JD

HL7 Study Data Standards Project Crystal Allard CDER Office of Computational Science Food and Drug Administration February 13,

Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.

1 Safety Pharmacology for Oncology Pharmaceuticals at CDER John K. Leighton Associate Director for Pharmacology CDER/OND/OODP.

ICH V1 An FDA Update Min Chen, M.S., RPh Office of Drug Safety Center for Drug Evaluation and Research FDA January 21, 2003.

Drug Development Lynnda Reid, Ph.D. Pharmacology/Toxicology Reviewer

MODULE B: Case Report Forms Jane Fendl & Denise Thwing April 7, Version: Final 07-Apr-2010.

Exploratory IND Studies

Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.

Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.

University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.

1Presentation Name Pre-Marketing Safety Assessment: The Safety Review Guidance Armando Oliva, M.D. Associate Director for Policy Office of New Drugs.

CLINICAL TRIALS IN NEW DRUG DEVELOPMENT Michael A Ross,M.D. President CPL Inc.

UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

The New Drug Development Process (www. fda. gov/cder/handbook/develop

Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.

ICH and CTD November 19, 2002 Kimberly Stranick, Ph.D. Worldwide Regulatory Affairs The Common Technical Document.

FDA Office of Orphan Products Development

UPDATE: Nonclinical Reproductive Toxicity Information in Assessing Human Risk Joseph J. DeGeorge Ph.D. Associate Director for Pharmacology and Toxicology.

Chief, Gene Therapy Branch

1 Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products Martin D. Green, Ph.D. Supervisory Pharmacologist DBOP/OODP/CDER.

FDA ICH Public Meeting 5630 Fishers Lane, Rockville, MD May 8, :30 am -- 2:00 pm Implementation of the CTD Update-Issues-Next Steps Justina A. Molzon,

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

James G. Farrelly, Ph.D. Pharmacology Team Leader Division of Antiviral Drug Products Center for Drug Evaluation and Research Food and Drug Administration.

Introduce GLP/GCP into China Shixin XU, PhD, Prof. China IVDC.

Preclinical Submissions to the FDA From Reviewer’s Perspective Harry M. Geyer, PhD Manager, Regulatory Affairs Teva USA (305)

GCP (GOOD CLINICAL PRACTISE)

TOPRA Annual Veterinary Symposium Introduction to the Case Study A presentation by Lesley Reeve, Module leader.

Drug Development Process Stages involved in Regulating Drugs

Design of Case Report Forms

for Human Pharmaceuticals Kyung-Chul Choi D.V.M., Ph.D.

Drug Discovery &Development

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Pre-Investigational New Drug (pre-IND) Meeting with FDA

CTD Content Management

Nonclinical Information in the Common Technical Document: Opportunities for Content Reuse Peggy Zorn, MPI Research Susan Mattano, Pfizer, Inc.

STF-Study tagging file

CTD Module 4: Non-Clinical Studies SPC Relevant Scientific information

Fundamentals of Electronic Submissions and eCTD

IND Review Process Seoul National University

Presentation transcript:

CDER IND/NDA Reviews Guidance, The Common Technical Document and Good Review Practice John K. Leighton, Ph.D., DABT CDER/FDA

Overview Current IND/NDA review process FDA/ICH guidance Common Technical Document CDER Pharmacology Good Review Practice

Review Team Project Managers Medical Officers Pharmacologists/Toxicologists Chemists Pharmacokineticists Statisticians

Nonclinical Studies Pharmacodynamics/Pharmacology Pharmacokinetics Safety pharmacology Toxicology Genetic toxicity Reproductive toxicity Carcinogenicity

Goals of Nonclinical IND Studies Identify starting dose Identify organ toxicities and reversibility Guide dosing regimens and escalation schemes

Pharmacology Studies Pharmacological activity determined in nonclinical studies is generally of low relevance to safety (IND) and efficacy (NDA) decisions. Summary report,without individual animal records or individual study results, usually suffices.

Toxicology Study Design Pivotal for safety/start dose decision. Toxicology studies should mimic the schedule, duration, formulation, and route as that proposed for the clinical trial. Conform to standard toxicology protocols. Conduct according to GLP.

Initial IND Development Integrated pharmacology/toxicology summary. Full tabulation of each toxicology study to support safety of proposed trial. Pharmacogenomic data: –Start dose selection? –Choice of relevant species? –Identify biomarkers?

IND/NDA Stage Long-term toxicology studies Genetic toxicology panel completed Reproductive toxicology Carcinogenicity studies (if necessary) Pharmacogenomic data: –Decrease study length? –Improve assessment of organ toxicity? –Provide mechanistic explanation of toxicity? Not replace standard assessment

Guidance FDA/ICH Represent current thinking of the Agency. Recommendations/not requirements. FDA Guidance –Draft (for comment purposes only) –Final

FDA/ICH Guidance Topics IND format Start dose selection Acute toxicity testing Electronic NDA submission Carcinogenicity Genetic toxicity Reproductive toxicity Photosafety testing Immunotoxicology Biotechnology

The Common Technical Document Guidance describing harmonized format for technical documentation for registration in all three regions. –Modules 2-5 common to all regions –Reduces time and resources used to compile registration documentation Use with other ICH and Agency guidance. Allows for regional specific summaries.

Good Review Practice Guidance for Reviewers: Pharmacology/Toxicology Review Format Internal review format for IND and NDA primary reviews Purpose –standardization of reviews across divisions –ensure that important information is captured –allows for continued assessment of IND Consistent with ICH CTD

Good Review Practice General Toxicology Study Results:Mortality Clinical Signs Body Weights Food Consumption Ophthalmoscopy Electrocardiography Hematology Clinical Chemistry Urinalysis Organ Weights Gross Pathology Histopathology Toxicokinetics

SUMMARY Different submission format for pivotal safety data. Good review practices for evaluation of data; provides consistency among review divisions and transparency. GRP will need to consider interdiscliplinary review of pharmacogenomic data. Pharmacogenomics may play an important role in safety assessment in future INDs and NDAs.